Technical Analysis for ENTA - Enanta Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Gapped Up | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Up 5 Days in a Row | Strength | 0.00% | |
| NR7 | Range Contraction | 1.24% | |
| Wide Bands | Range Expansion | 1.24% | |
| Up 3 Days in a Row | Strength | 1.24% | |
| Up 4 Days in a Row | Strength | 1.24% | |
| Inside Day | Range Contraction | 3.33% | |
| Wide Bands | Range Expansion | 3.33% |
| Alert | Time |
|---|---|
| 10 DMA Support | about 14 hours ago |
| 60 Minute Opening Range Breakdown | about 15 hours ago |
| Up 3% | about 16 hours ago |
| Up 2% | about 17 hours ago |
| Rose Above Previous Day's High | about 17 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 08/05/2024
Enanta Pharmaceuticals, Inc. Description
Enanta Pharmaceuticals, Inc., a biotechnology company, engages in the development of small molecule drugs for the infectious disease areas. Its product candidates include ABT-450, an inhibitor of NS3 protease that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV) infection; EDP-239, an NS5A Inhibitor for HCV infection; EDP-546, a Cyclophilin inhibitor, which is in preclinical studies for HCV infection treatment; and Nucleotide Polymerase inhibitor for HCV infection. The company also develops EDP-788, an intravenous drug for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc. and Abbott Laboratories. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Infectious Diseases Chemical Compounds Infection Medical Research Viruses Hepatitis C Hepatitis C Virus HCV Staphylococcus Aureus Cyclophilin Treatment Of Hepatitis Cyclopropanes Methicillin HCV Infection Pyrrolidines
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 20.02 |
| 52 Week Low | 8.08 |
| Average Volume | 186,263 |
| 200-Day Moving Average | 12.32 |
| 50-Day Moving Average | 13.33 |
| 20-Day Moving Average | 14.64 |
| 10-Day Moving Average | 15.31 |
| Average True Range | 0.81 |
| RSI (14) | 61.98 |
| ADX | 34.08 |
| +DI | 31.09 |
| -DI | 13.47 |
| Chandelier Exit (Long, 3 ATRs) | 14.79 |
| Chandelier Exit (Short, 3 ATRs) | 14.32 |
| Upper Bollinger Bands | 16.75 |
| Lower Bollinger Band | 12.53 |
| Percent B (%b) | 0.71 |
| BandWidth | 28.87 |
| MACD Line | 0.59 |
| MACD Signal Line | 0.60 |
| MACD Histogram | -0.0114 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.47 | ||||
| Resistance 3 (R3) | 16.47 | 16.14 | 16.31 | ||
| Resistance 2 (R2) | 16.14 | 15.90 | 16.15 | 16.26 | |
| Resistance 1 (R1) | 15.83 | 15.75 | 15.67 | 15.84 | 16.21 |
| Pivot Point | 15.51 | 15.51 | 15.43 | 15.51 | 15.51 |
| Support 1 (S1) | 15.20 | 15.27 | 15.04 | 15.20 | 14.83 |
| Support 2 (S2) | 14.87 | 15.12 | 14.88 | 14.78 | |
| Support 3 (S3) | 14.56 | 14.87 | 14.73 | ||
| Support 4 (S4) | 14.57 |
